 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Sepracor Inc.
 |
Sepracor Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Sepracor loss widens on higher research spending Jul 23 2001 04:29 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
For Sepracor, "new and improved" is the name of the game. The company develops and commercializes new, patented forms of existing pharmaceuticals by purging them of nonessential -- or even deleterious -- molecules. Compared to their traditional-compound counterparts, Sepracor's products (called improved chemical entities, or ICEs) can reduce side effects, provide new uses, and improve safety, performance, and dosage. Sepracor focuses its ICE efforts on gastroenterology, neurology, psychiatry, respiratory care, and urology. The firm is also developing its own new drugs to treat infectious diseases and central nervous system disorders.
COMPETITION |
 |
Barr Laboratories, Inc. (BRL)
GlaxoSmithKline plc (GSK)
Johnson & Johnson (JNJ)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 85.20
1-Yr. Sales Growth: 275.3%
Employees: 499
Revenue per employee: $170,741.48
KEY PEOPLE |
 |
Timothy J. Barberich
CEO
David P. Southwell
CFO
CONTACT INFO |
 |
111 Locke Dr.
Marlborough, MA 01752
US
Phone: 508-481-6700
Fax: 508-357-7499
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |